Literature DB >> 31568988

Systematic screening of protein-coding gene expression identified HMMR as a potential independent indicator of unfavorable survival in patients with papillary muscle-invasive bladder cancer.

Dong Yang1, Yan Ma1, Pengcheng Zhao1, Jing Ma1, Chaohong He2.   

Abstract

Papillary and non-papillary are two histological patterns of bladder carcinogenesis and are considered as dual-track oncogenic pathways, which have different genetic alterations. The TCGA-bladder cancer (BLCA) database contains clinicopathological, genomic and survival data from over 400 muscle-invasive bladder cancer patients. In this study, using data from this database, we performed a systematic screening of gene expression to identify the protein-coding gene that might have prognostic value in papillary and non-papillary muscle-invasive bladder cancer (MIBC). The data of patients with primary MIBC in TCGA-BLCA was acquired from the UCSC Xena project (http://xena.ucsc.edu) for re-analysis. By setting |log2 fold change|≥2 and adjusted p value <0.01 as the screening criteria, we found 751 significantly dysregulated genes, including 183 overexpressed and 568 downregulated genes. HMMR was identified as a potential prognostic marker with unique expression. Multivariate analysis showed that its expression was an independent prognostic indicator of shorter progression-free survival (PFS) (HR: 1.400, 95%CI: 1.021-1.920, p = 0.037) in the papillary subtype. ENST00000393915.8 and ENST00000358715.3, two transcripts that contain all 18 exons and encode the full length of HMMR, were significantly upregulated in cancer tissues compared with normal bladder tissues. None of the 17 CpG sites in its DNA locus was relevant to HMMR expression. 26/403 (6.5%) MIBC cases had HMMR gene-level amplification, which was associated with upregulated HMMR expression compared with the copy-neutral and deletion groups. Gene set enrichment analysis (GSEA) in papillary MIBC found that the high HMMR expression group was associated with upregulated genes enriched in multiple gene sets with well-established role in BC development, including G2M checkpoint, E2 F Targets, Myc Targets V1, Myc Targets V2 and Glycolysis. Based on these findings, we infer that HMMR expression might be a specific prognostic marker in terms of PFS in papillary MIBC. DNA amplification might be an important mechanism of its elevation.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  HMMR; Muscle-invasive bladder cancer; Non-papillary; Papillary; Prognosis

Mesh:

Substances:

Year:  2019        PMID: 31568988     DOI: 10.1016/j.biopha.2019.109433

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  10 in total

1.  A Novel Prognostic Index Based on the Analysis of Glycolysis-Related Genes in Head and Neck Squamous Cell Carcinomas.

Authors:  Yuchao Liu; Shihua Yin
Journal:  J Oncol       Date:  2020-09-24       Impact factor: 4.375

2.  A glycolysis-related gene pairs signature predicts prognosis in patients with hepatocellular carcinoma.

Authors:  Weige Zhou; Shijing Zhang; Zheyou Cai; Fei Gao; Wenhui Deng; Yi Wen; Zhen-Wen Qiu; Zheng-Kun Hou; Xin-Lin Chen
Journal:  PeerJ       Date:  2020-09-29       Impact factor: 2.984

3.  Comprehensive analysis of the relationship between competitive endogenous RNA (ceRNA) networks and tumor infiltrating-cells in hepatocellular carcinoma.

Authors:  Jun Zhu; Liang Wang; Yifan Zhou; Jun Hao; Shuai Wang; Lei Liu; Jipeng Li
Journal:  J Gastrointest Oncol       Date:  2020-12

4.  Development of prognostic signature based on immune-related genes in muscle-invasive bladder cancer: bioinformatics analysis of TCGA database.

Authors:  Kun Jin; Shi Qiu; Di Jin; Xianghong Zhou; Xiaonan Zheng; Jiakun Li; Xinyang Liao; Lu Yang; Qiang Wei
Journal:  Aging (Albany NY)       Date:  2021-01-19       Impact factor: 5.682

5.  Prognostic implication of glycolysis related gene signature in non-small cell lung cancer.

Authors:  Jie Yao; Rui Li; Xiao Liu; Xijia Zhou; Jianping Li; Tingting Liu; Chen Huo; Yiqing Qu
Journal:  J Cancer       Date:  2021-01-01       Impact factor: 4.207

6.  The Prognostic Value and Immune Landscapes of a m6A/m5C/m1A-Related LncRNAs Signature in Head and Neck Squamous Cell Carcinoma.

Authors:  Enhao Wang; Yang Li; Ruijie Ming; Jiahui Wei; Peiyu Du; Peng Zhou; Shimin Zong; Hongjun Xiao
Journal:  Front Cell Dev Biol       Date:  2021-11-30

Review 7.  The role of RHAMM in cancer: Exposing novel therapeutic vulnerabilities.

Authors:  Josephine A Hinneh; Joanna L Gillis; Nicole L Moore; Lisa M Butler; Margaret M Centenera
Journal:  Front Oncol       Date:  2022-08-10       Impact factor: 5.738

8.  Identification of novel hub genes associated with gastric cancer using integrated bioinformatics analysis.

Authors:  Xiao-Qing Lu; Jia-Qian Zhang; Sheng-Xiao Zhang; Jun Qiao; Meng-Ting Qiu; Xiang-Rong Liu; Xiao-Xia Chen; Chong Gao; Huan-Hu Zhang
Journal:  BMC Cancer       Date:  2021-06-14       Impact factor: 4.430

9.  Autophagy characteristics and establishment of autophagy prognostic models in lung adenocarcinoma and lung squamous cell carcinoma.

Authors:  Zhubei Chen; Hui Xiong; Hao Shen; Qingsheng You
Journal:  PLoS One       Date:  2022-03-25       Impact factor: 3.240

10.  Identification of hub genes associated with prognosis, diagnosis, immune infiltration and therapeutic drug in liver cancer by integrated analysis.

Authors:  Xinyi Lei; Miao Zhang; Bingsheng Guan; Qiang Chen; Zhiyong Dong; Cunchuan Wang
Journal:  Hum Genomics       Date:  2021-06-29       Impact factor: 4.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.